The 2022 G-FINDER Report reveals that for the year 2021, global funding for the development of critical new health technologies to overcome the world’s deadliest neglected diseases remained woefully inadequate and largely stagnant. The report highlights an alarming decline in global investment in product development partnerships (PDPs) for the research and development of medical innovations to address neglected diseases. PDPs are global leaders in developing new health technologies for Poverty Related Neglected Diseases for which there are scarce commercial incentives. TB Alliance’s six-month treatment for drug- resistant TB is a testament to what PDPs can deliver when sufficiently resourced. Despite this track record, PDP funding declined steeply in 2021, a reduction of nearly $100M, marking a record low for the fifteen years over which G-FINDER has tracked these figures. Read more here.
top of page
Recent Posts
See AllThe Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
350
Calls for strengthening health systems in preparation for the next pandemic have intensified in the wake of COVID-19, with estimates ranging from $15 billion to $50 billion needed annually to scale up
540
The monitoring and evaluation framework of the TB Action Plan for the WHO European Region 2023–2030 includes four new indicators reflecting consistent meaningful engagement of the communities and civi
540
bottom of page